Terrence W. Norchi, MD, our co-founder, serves as our President and Chief Executive Officer, and he is a director on our Board of Directors. Dr. Norchi has served in similar positions since co-founding ABS, our predecessor company in 2006. Prior to ABS, Dr. Norchi was portfolio manager of one of the world’s largest healthcare mutual funds and pharmaceutical analyst at Putnam Investments. Prior to that he served as the senior global biotech and international pharmaceutical equity analyst at Citigroup Asset Management, and as a sell-side analyst covering non-U.S. pharmaceutical equities at Sanford C. Bernstein in New York City.
Dr. Norchi earned an M.B.A. from the Massachusetts Institute of Technology, Sloan School of Management in 1996. Dr. Norchi earned an M.D. degree in 1990 from Northeast Ohio Medical University and completed his internal medicine residency in 1994 at Baystate Medical Center, Tufts University School of Medicine, where he was selected to serve as the Chief Medical Resident.
Dr. Norchi brings to our Board of Directors and management team invaluable experience and knowledge of our core technology and proposed product candidates as a result of his first-hand experience with the development of that technology, having ushered it from the research laboratory to its current stage of development. He is a primary inventor on many of our patents. His investing experience as a former public company analyst and a portfolio manager provides further insights and value as the company advances toward commercialization.
Dr. Norchi serves on the Board of Advisors of the Boston Museum of Science.
Mr. Sulat joined our Board of Directors in August 2015. Mr. Sulat also serves as the Chairman of the Board of Directors for Momenta Pharmaceuticals, Inc., a biotech company focused on the analysis, characterization and design of complex pharmaceutical products. Mr. Sulat has served as a member of the Supervisory Board for Valneva SE or its predecessor company, Intercell AG, both European biotech companies focusing on vaccines, since 2005. Mr. Sulat has served as a member of the Board of Directors for AMAG Pharmaceuticals, Inc., a pharmaceutical company focused on the development and commercialization of specialty pharmaceutical products, since 2014. Mr. Sulat has served as a member of the Board of Directors for diaDexus, Inc., a molecular diagnostics company focused on cardiovascular disease, since 2015. Previously, Mr. Sulat served as the Chief Executive Officer and Chief Financial Officer for Maxygen, Inc., from 2009 to 2013. Mr. Sulat also served as a member of the Board of Directors for Maxygen, Inc., from 2003 to 2013. Prior to that, Mr. Sulat served as the Chief Executive Officer, Chief Financial Officer and a member of the Board of Directors for Memory Pharmaceuticals Corp., from 2005 to 2008. Mr. Sulat previously served in senior executive roles for R.R. Donnelley & Sons, Co., Chiron Corporation, Stanford Health Services, Inc., and Esprit de Corp, Inc. Mr. Sulat also previously served as a member of the Board of Directors for Codexis, Inc., Ariat International, Inc., General Surgical Innovations, Inc., and Vans, Inc. Mr. Sulat received a B.S. in Administrative Sciences from Yale University, and an M.B.A. and an M.S. in Health Services Administration from Stanford University.
Mr. Dhillon joined our Board of Directors in July 2018. Mr. Dhillon brings over 15 years of global industry experience to Arch's Board with a wealth of knowledge and experience operationally in medical devices, advancing programs from scientific research through clinical development, regulatory approval, and into healthcare systems globally. Mr. Dhillon's business and management experience includes corporate finance, integration, intellectual property licensing, strategy implementation, mergers and acquisitions and collaborations with academic and other institutions. Strategic partnerships established by Mr. Dhillon include early and late stage deals with Merck and Pfizer. Mr. Dhillon co-founded OncoSec, a biotechnology company pioneering new technologies to stimulate the body's immune system to target and attack cancer. Prior to that, Mr. Dhillon served as Vice President of Finance and Operations at Inovio Pharmaceuticals, Inc. (formerly Inovio Biomedical Corporation), a DNA vaccine development company, from September 2003 until March 2011. Mr. Dhillon is also currently a director for Emerald Health Sciences, Inc. and Audit Committee Chair of Emerald Health Therapeutics, Inc. (TSXV: EMH) and Nemus Bioscience, Inc. (OTCQB: NMUS). Mr. Dhillon was recognized as one of the "Top 100 CEOs" by PharmaVoice in 2013, as "Most Admired CEO" by The San Diego Business Journal in 2016, and as a finalist for Ernst & Young's Annual "Entrepreneur of the Year." Mr. Dhillon has a Bachelor of Arts with honors in Political Science and a minor in Business Administration from Simon Fraser University.
Mr. Davis brings a proven and successful record of more than 25 years of progressive and diversified business, financial and operational leadership within both publicly traded and privately held, domestic and multinational companies. Most recently, he has been an advisor to small and mid-size companies assisting them in their accounting, financial reporting, investor and banking needs. Prior to that, he was President, Chief Operating Officer and Chief Financial Officer at NMT Medical, Inc., a NASDAQ-traded medical device company. In this role he developed and executed strategic and operational plans that resulted in revenue growth of 35 percent, 13 consecutive quarters of profitability, increased stock price and analyst coverage from five major investment firms; directed the stabilization of a French subsidiary and led successful efforts in raising $6 million from institutional investors to fund ongoing FDA-approved clinical trials. Prior to that, he was Vice President and Chief Financial Officer at Q-Peak, Inc., where he oversaw all financial and administrative functions. Earlier, he worked in a variety of senior level positions at the Coleman Company, The TJX Companies, Inc. and Wang Laboratories. He holds a Master of Business Administration degree with a Finance concentration from Babson College and a Bachelor of Business Administration degree from the University of Massachusetts Amherst.
Chirag B. Shah, PhD is Vice President of Research and Development Engineering and Quality Systems at Arch Therapeutics. Dr. Shah brings broad 20 years of proven record of technology and product development, advanced research and device performance evaluations covering vascular, advanced wound care and infection control products. Prior to joining Arch Therapeutics, Dr. Shah was a Senior Director of Biomaterials R&D Center of Excellence in Vascular Therapies GBU at Covidien for 10 years and contributed to peripheral and neurovascular, wound care and renal access products and technologies development. Earlier, Dr. Shah worked at Biolink Corporation focusing on development of a liquid device product for infection and clotting prevention. Prior to that, Dr. Shah worked at USCI division of C.R. Bard, focusing on myocardial bioactive implant and thromboresistant stent coating technologies.
Dr. Shah earned a PhD from University of Rhode Island in 1993 and Executive Leadership Certificates from Cornell and MIT in 2011 and 2009, respectively. Dr. Shah is listed as co-inventor on 25 US issued patents and published applications.
Mr. Wadsworth, an advisor to Arch as of 2019, has more than 30 years of experience leading innovation in scientific and engineering enterprises and driving value in public and private life science companies. He has commercialized over 100 medical device technology advancements in fields including wound healing, cancer drug delivery, ESRD, atherosclerotic disease, and orthopedics. Mr. Wadsworth has held executive leadership roles in medical device companies such as CR Bard (BD) and KCI (Acelity), and he has had responsibility for Commercialization, Research and Development, Quality and Regulatory organizations. He is also an entrepreneur, co-founder and COO of Metric Medical Devices, Inc. and is the recipient of two US patents in chemotherapy drug delivery.
Mr. Wadsworth has a BS in Biology from the University of New York at Albany and a Masters in Biomedical Engineering from Worcester Polytechnic Institute.